D. Cangini

发表

Up-Front Thalidomide-Dexamethasone (THAL) and Double Autologous Transplantation (Double TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic Implications of Chromosome 13 Deletion and Translocation t(4;14).

M. Baccarani, G. Martinelli, T. Grafone, 2006 .

Reversible, PET-positive, generalized lymphadenopathy and splenomegaly during high-dose interferon-alpha-2b adjuvant therapy for melanoma.

V. Chiarion-Sileni, A. Moretti, R. Galassi, 2008, Journal of immunotherapy.

Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results

C. Nanni, S. Fanti, M. Farsad, 2006, European Journal of Nuclear Medicine and Molecular Imaging.

A prospective comparison of 18 F-fluorodeoxyglucose positron emission tomography-computed tomography , magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma

R. Fanin, M. Baccarani, C. Nanni, 2007 .

Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.

M. Baccarani, E. Zamagni, F. Di Raimondo, 2006, Blood.

Prolonged 18FDG‐PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd‐G)

D. Amadori, F. Matteucci, S. Asioli, 2011, American journal of hematology.

CPX-351 - Daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.

G. Martinelli, G. Simonetti, C. Cerchione, 2020, Minerva medica.

Superiority of Double over Single Autologous Stem Cell Transplantation as First-Line Therapy for Multiple Myeloma.

M. Baccarani, E. Zamagni, S. Tura, 2004 .

Involvement of the MLL gene in T-lineage acute lymphoblastic leukemia

E. Zamagni, G. Palareti, P. Tosi, 2002 .

Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation.

S. Pileri, M. Baccarani, T. Grafone, 2001, Haematologica.

First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.

Sante Tura, Michele Cavo, Patrizia Tosi, 2004, Haematologica.

Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.

M. Baccarani, A. Neri, G. Martinelli, 2003, Blood.

Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope.

G. Martinelli, G. Simonetti, C. Cerchione, 2020, Minerva medica.

Neuropathy in multiple myeloma treated with thalidomide

R. Michelucci, F. Salvi, C. Tassinari, 2007, Neurology.

Complete remission upon bortezomib–dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation

M. Baccarani, E. Zamagni, P. Tosi, 2006, Annals of Hematology.

Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.

M. Baccarani, E. Zamagni, F. Di Raimondo, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bisphosphonates and Osteonecrosis of the Jaws: Incidence in a Homogeneous Series of Patients with Newly Diagnosed Multiple Myeloma Treated with Zoledronic Acid.

M. Baccarani, E. Zamagni, S. Tura, 2005 .

Neurological toxicity of long‐term (>1 yr) thalidomide therapy in patients with multiple myeloma

M. Baccarani, E. Zamagni, S. Tura, 2005, European journal of haematology.

Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.

M. Gobbi, M. Baccarani, E. Zamagni, 2002, Haematologica.

preparation for autologous transplantation for multiple myeloma vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in Superiority of thalidomide and dexamethasone over

M. Baccarani, T. Grafone, E. Zamagni, 2013 .

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

M. Baccarani, T. Grafone, E. Zamagni, 2005, Blood.

A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.

R. Fanin, M. Baccarani, C. Nanni, 2007, Haematologica.

Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and feature.

G. Martinelli, G. Simonetti, M. Gottardi, 2020, Minerva medica.

First‐line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma

M. Baccarani, E. Zamagni, S. Tura, 2006, European journal of haematology.

Superiority of First-Line Thalidomide-Dexamethasone over Vincristine-Doxorubicin-Dexamethasone in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.

M. Baccarani, E. Zamagni, S. Tura, 2004 .

Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.

M. Baccarani, E. Zamagni, G. Palareti, 2002, Blood.

Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure

M. Baccarani, E. Zamagni, S. Tura, 2004, European journal of haematology.

Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission.

M. Baccarani, G. Martinelli, T. Grafone, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Superior PFS2 with VTD Vs TD for Newly Diagnosed, Transplant Eligible, Multiple Myeloma (MM) Patients: Updated Analysis of Gimema MMY-3006 Study

P. Galieni, E. Zamagni, P. Tosi, 2014 .

IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia

D. Amadori, G. Martinelli, S. Carloni, 2015, Journal of Translational Medicine.

Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial

V. Martinelli, G. Martinelli, G. Simonetti, 2020, Journal of clinical medicine.

Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.

M. Baccarani, E. Zamagni, P. Musto, 2008 .

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations

G. Martinelli, G. Simonetti, A. Ferrari, 2023, Frontiers in Cell and Developmental Biology.

Role of 18f-FDG PET/CT in the Management of Multiple Myeloma.

M. Baccarani, C. Nanni, S. Fanti, 2005 .

bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use

M. Baccarani, A. Neri, G. Martinelli, 2002 .